D-Amino Acid Interfering Peptide NIP-V Targets SARS-CoV-2 N Protein
Solution Overview
Problem
Current treatments for SARS-CoV-2 infections lack effective small-molecule drugs, with existing options like hydroxychloroquine and remdesivir showing questionable efficacy, and plasma therapy being risky and limited in scalability.
Innovation Solution
A preparation method for an interfering peptide, NIP-V, targeting the SARS-CoV-2 N protein, involving design of a peptide segment within the dimerization domain, fusion with HIV-TAT, and modification into a D-amino acid sequence, which can inhibit viral replication and proliferation by disrupting protein-protein interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small-molecule drugs are used for SARS-CoV-2 treatment, then the development cycle is extended, but the efficacy is questionable
Solution Approach 1:
The patent uses peptide copying to create NIP-V, a peptide that mimics and interferes with the SARS-CoV-2 N protein's dimerization function. Instead of developing new small-molecule drugs through lengthy trials, the invention directly synthesizes a peptide copy that replicates the target protein's interaction interface, achieving rapid therapeutic effect with proven mechanism
Solution Approach 2:
The patent modifies the peptide structure by incorporating D-amino acids instead of natural L-amino acids. This parameter change in chirality confers resistance to proteolytic degradation, significantly improving the peptide's stability and half-life in vivo while maintaining its ability to interfere with viral protein dimerization
2Reliability
If plasma therapy is used for SARS-CoV-2 treatment, then treatment effect is achieved, but scalability is limited and risks exist
Solution Approach 1:
The patent replaces expensive, scarce plasma with a synthetically produced peptide drug NIP-V that can be manufactured at scale through chemical synthesis. The peptide is a stable, non-immunogenic molecule that can be produced on demand without relying on human plasma donors, making treatment accessible and scalable
Solution Approach 2:
The patent creates a defined peptide intermediary (NIP-V) that mediates the therapeutic effect by specifically binding to and interfering with the SARS-CoV-2 N protein dimerization. This replaces the complex, undefined mixture of antibodies and proteins in plasma with a single, well-characterized molecular entity that has predictable pharmacokinetics and mechanism of action
3Reliability
If interfering peptide NIP-V is designed to block protein-protein interactions, then viral replication is inhibited, but peptide stability and delivery challenges arise
Solution Approach 1:
The patent inverts the natural L-amino acid configuration to use D-amino acids throughout the peptide sequence. This chiral inversion fundamentally changes the peptide's susceptibility to proteolysis, as cellular proteases are evolved to recognize and cleave L-amino acid sequences. The D-peptide configuration confers exceptional stability while preserving the ability to form bioactive structures that interfere with viral protein dimerization
Solution Approach 2:
The patent creates a composite peptide structure that combines the HIV-TAT cell-penetrating sequence with the SARS-CoV-2 N protein dimerization interference sequence. This composite design integrates two functional elements: TAT enables cellular uptake while the N-protein-targeting segment blocks viral replication, achieving both delivery and therapeutic function in a single molecule
Data Source
AI summary
A preparation method of an interfering peptide targeting SARS-CoV-2 N protein includes the following steps: designing an interfering peptide segment targeting amino acids located in a dimerization domain of the SARS-CoV-2 N protein; fusing the interfering peptide segment with HIV-TAT; modifying the interfering peptide segment fused with HIV-TAT into a reverse isomer to obtain an amino acid sequence of a final interfering peptide NIP-V; and synthesizing the interfering peptide NIP-V using D-amino acids as raw materials. The above-mentioned interfering peptide drug NIP-V is able to interact with the dimerization domain of the SARS-CoV-2 N protein, inhibit the oligomerization of N protein, and then relieve the inhibition for innate immunity by the N protein, so as to achieve the purpose of inhibiting the replication of SARS-CoV-2 virus in cells and animals.



